JP2024511449A - Kv1.3遮断薬 - Google Patents

Kv1.3遮断薬 Download PDF

Info

Publication number
JP2024511449A
JP2024511449A JP2023558496A JP2023558496A JP2024511449A JP 2024511449 A JP2024511449 A JP 2024511449A JP 2023558496 A JP2023558496 A JP 2023558496A JP 2023558496 A JP2023558496 A JP 2023558496A JP 2024511449 A JP2024511449 A JP 2024511449A
Authority
JP
Japan
Prior art keywords
amino acid
seq
ion channel
side chain
channel blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511449A5 (cg-RX-API-DMAC7.html
Inventor
ヘンリク フィスカー ムンク
Original Assignee
ジーランド ファーマ エー/エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー/エス filed Critical ジーランド ファーマ エー/エス
Publication of JP2024511449A publication Critical patent/JP2024511449A/ja
Publication of JP2024511449A5 publication Critical patent/JP2024511449A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023558496A 2021-03-23 2022-03-22 Kv1.3遮断薬 Pending JP2024511449A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21164384 2021-03-23
EP21164384.6 2021-03-23
EP21213431 2021-12-09
EP21213431.6 2021-12-09
PCT/EP2022/057533 WO2022200374A1 (en) 2021-03-23 2022-03-22 Kv1.3 blockers

Publications (2)

Publication Number Publication Date
JP2024511449A true JP2024511449A (ja) 2024-03-13
JP2024511449A5 JP2024511449A5 (cg-RX-API-DMAC7.html) 2025-03-27

Family

ID=80952156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558496A Pending JP2024511449A (ja) 2021-03-23 2022-03-22 Kv1.3遮断薬

Country Status (12)

Country Link
US (1) US20240182531A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314024A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511449A (cg-RX-API-DMAC7.html)
KR (1) KR20230159403A (cg-RX-API-DMAC7.html)
AU (1) AU2022245193A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019022A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208713A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002590A1 (cg-RX-API-DMAC7.html)
IL (1) IL305219A (cg-RX-API-DMAC7.html)
MX (1) MX2023010930A (cg-RX-API-DMAC7.html)
TW (1) TW202304957A (cg-RX-API-DMAC7.html)
WO (1) WO2022200374A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4604984A1 (en) * 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド
WO2021053194A1 (en) * 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8429751B2 (en) 2009-03-13 2013-04-23 Trustwave Holdings, Inc. Method and apparatus for phishing and leeching vulnerability detection
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
JP2016527250A (ja) 2013-07-22 2016-09-08 キネタ ワン リミテッド ライアビリティ カンパニーKineta One,Llc 毒素系治療用ペプチド及びその医薬組成物の眼科的使用
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド
WO2021053194A1 (en) * 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers

Also Published As

Publication number Publication date
US20240182531A1 (en) 2024-06-06
CA3208713A1 (en) 2022-09-29
EP4314024A1 (en) 2024-02-07
CL2023002590A1 (es) 2024-03-15
AU2022245193A1 (en) 2023-09-07
IL305219A (en) 2023-10-01
BR112023019022A2 (pt) 2023-10-17
WO2022200374A1 (en) 2022-09-29
KR20230159403A (ko) 2023-11-21
TW202304957A (zh) 2023-02-01
MX2023010930A (es) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7703520B2 (ja) Kv1.3遮断剤
US10905745B2 (en) Acylated GLP-1/GLP-2 dual agonists
KR102587196B1 (ko) Glp-1/glp-2 이중 효능제
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
KR20260038313A (ko) 글리피칸-3을 표적화하는 펩티드 조성물 및 그의 용도
US20240182531A1 (en) KV1.3 Blockers
RU2825633C1 (ru) БЛОКАТОРЫ Kv1.3
CN117255798A (zh) Kv1.3阻断剂
JP2025534884A (ja) 阻害剤
HK40111792A (en) Acylated glp-1/glp-2 dual agonists
HK40007709A (en) Acylated glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260407